ArticleCancer diagnosis & prognosis
Value of Carcinoembryonic Antigen Levels After Chemoradiotherapy for Advanced Low Rectal Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is the standard treatment for advanced low rectal cancer; however, long-term oncological outcomes vary widely, and reliable prognostic biomarkers remain limited. Carcinoembryonic antigen (CEA) is commonly used in colorectal cancer management, but the prognostic value of post-CRT CEA levels has not been fully clarified. This study aimed to identify clinically relevant prognostic factors for recurrence and survival, with particular focus on pre- and post-CRT CEA levels. Patients and Methods: A retrospective review was conducted of 41 consecutive patients with advanced low rectal cancer (Rb, cT3/4 or N1/2 and no lateral lymph node metastasis) who underwent long-course preoperative CRT followed by radical surgery. CRT consisted of 45 Gy in 25 fractions with concurrent tegafur/uracil, followed by total mesorectal excision 8-10 weeks after CRT completion. Clinicopathological factors were analyzed in relation to recurrence, disease-free survival (DFS), and overall survival (OS). Results: With a median follow-up of 69.3 months, recurrence occurred in 16 patients. Five-year DFS and OS rates were 59.4% and 73.2%, respectively. Univariate analysis identified postoperative complications, pathological complete response, and pre- and post-CRT CEA levels as significant factors associated with recurrence. Multivariate analysis demonstrated that post-CRT CEA was the only independent prognostic factor. Receiver operating characteristic analysis identified a post-CRT CEA cut-off value of 3.9 ng/ml. Patients with lower post-CRT CEA showed significantly better DFS and OS. Conclusion: Post-CRT CEA is a valuable prognostic biomarker for recurrence and survival in advanced low rectal cancer, and patients with elevated post-CRT CEA may benefit from additional consolidation chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.